Negev Capital
company
About
Negev Capital primarily target companies with medications that are at early stage of clinical development.
- 1 - 10
Highlights
Details
- Industries
- Biotechnology,Pharmaceutical
- Founded date
- Jan 7, 2021
- Number Of Employee
- 1 - 10
- Operating Status
- Active
- Investor Type
- Venture Capital
Negev Capital is a psychedelic medical intervention investment fund with assets of USD$20+ million. We invest in drug discovery, with a focus on preclinical and/or Phase 1 stages of development. We aim to support those early stage companies in need of capital that promote the thoughtful, responsible, medical use of psychedelic medication for psychiatric disorders, and who have excellent management and science teams, and solid IP.
Investments
Number of Investments
Number of Lead Investments
1
0
Negev Capital has made 1 investments. Their most recent investment was on
Dec 15, 2022, when Gilgamesh Pharmaceuticals raised $39M.
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Dec 15, 2022
Gilgamesh Pharmaceuticals
|
Series B | $39M | Biotechnology | — |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
